Serious harms from medical devices jump nearly three times
The Indian Pharmacopoeia Commission has, for the first time, shared figures on serious harms linked to medical devices. Yearly serious reports rose from 808 to 2,176 in 2025 — nearly three times. Read it to revise materiovigilance, CDSCO and why brand details stay hidden under the RTI Act.
- Serious reports since 2020
- 9,373
- 2025 yearly SAEs
- 2,176 (from 808)
- Monitoring centres
- 775 under MvPI
- Sent to CDSCO in 2024-25
- Only 22 of 14,584 events
Device harms: what happened?
Stents, implants and other devices save lives — but when they harm, India has shared little public data until now.
- The Indian Pharmacopoeia Commission disclosed 9,373 Serious Adverse Events linked to medical devices since 2020.
- Yearly serious reports rose from 808 to 2,176 in 2025 — nearly a three-fold jump.
- The data came after a Central Information Commission order on an RTI appeal by The Indian Express.
- In 2024-25 the Commission logged 14,584 device adverse events but sent only 22 cases to the Central Drugs Standard Control Organisation for action.
- Brand and manufacturer details stay withheld as commercial confidence under Section 8(1)(d) of the RTI Act.
What is materiovigilance?
Materiovigilance means watching medical devices for harm after they are in use — like stents, implants, pacemakers and diagnostic tools.
India’s Materiovigilance Programme (MvPI) began in 2015. About 775 monitoring centres send adverse-event reports to the Indian Pharmacopoeia Commission.
A Serious Adverse Event is one that may cause death risk, long hospital stays, disability or other major harm, and must be reported within 15 days.
Device adverse events
| Point | Figure |
|---|---|
| Serious events since 2020 | 9,373 |
| Yearly SAEs 808 → | 2,176 in 2025 |
| MvPI centres | 775 |
| Events sent to CDSCO (2024-25) | 22 of 14,584 |
Which laws and Articles apply?
- Drugs and Cosmetics Act / Medical Devices Rules: regulate devices in India.
- Central Drugs Standard Control Organisation (CDSCO): national regulator for drugs and devices.
- RTI Act, Section 8(1)(d): exemption for commercial confidence.
- Article 21: right to health as part of life and liberty.
Why does medical device adverse events matter?
| Angle | What to note |
|---|---|
| Patient safety | Hidden harms cannot be fixed. |
| Regulation | Few cases reach CDSCO action. |
| Transparency | US MAUDE publishes more detail. |
| Trust | Patients and doctors need brand-level data. |
What are the problems with medical device adverse events?
- Brand names stay secret under RTI.
- Very few cases go to the regulator for action.
- Reporting may still undercount real harm.
- Patients rarely know how to report a device problem.
What should be done next on medical device adverse events?
- Publish anonymised brand-level safety data.
- Speed up CDSCO follow-up on serious cases.
- Train hospitals to report every serious event.
- Create a simple public helpline for device harms.
What can Prelims ask on medical device adverse events?
Prelims probability: Medium–High: first public SAE series, MvPI, CDSCO and RTI exemptions — strong health-governance Prelims hooks.
- MvPI: Materiovigilance Programme of India (2015).
- IPC receives device adverse-event reports.
- CDSCO is the national drugs and devices regulator.
- Serious events must be reported within 15 days.
- RTI Section 8(1)(d) used to withhold brand details.
How to write about medical device adverse events in Mains
Practice question (15 marks, 250 words): Patient safety needs transparent data on medical devices. Discuss India’s materiovigilance system in the light of the new SAE figures.
- Intro: jump in serious reports.
- What MvPI does.
- Action gap and opacity.
- Compare with open databases abroad.
- Conclusion: safety data must reach the public.
Ready lines for your answer
- A device that saves one life must not quietly harm another.
- Safety data hidden as commercial confidence still costs patients.
Quotable data pointOnly 22 of 14,584 device adverse events reached CDSCO for action in 2024-25.
Photo: AnjanBorah, CC BY-SA 4.0, via Wikimedia Commons
Exam angle
Prelims: CDSCO, MvPI, RTI exemptions. · Mains GS-II: health governance.
Practice MCQs
Original practice questions (not PYQs).
Consider the following statements:
1. The Indian Pharmacopoeia Commission disclosed Serious Adverse Events for medical devices since 2020.
2. Materiovigilance Programme of India began in 2015.
3. All serious device-event reports in 2024-25 were forwarded to CDSCO.
How many of the above statements are correct?
Answer (a) & explanation
Statements 1 and 2 are correct. Only 22 of 14,584 MDAEs in 2024-25 were forwarded to CDSCO.
Serious Adverse Events for medical devices must ordinarily be reported to the IPC within:
Answer (d) & explanation
Global and Indian practice cited requires SAE reporting to the IPC within 15 days.
Questions students ask about this
How many serious device events has IPC logged since 2020?
9,373 Serious Adverse Events.
How much did yearly serious reports rise?
From 808 to 2,176 in 2025 — nearly three times.
What is MvPI?
The Materiovigilance Programme of India, started in 2015, with about 775 monitoring centres.
Why are brand names hidden?
They are withheld as commercial confidence under Section 8(1)(d) of the RTI Act.